140 related articles for article (PubMed ID: 35315729)
1. Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study.
Kaku K; Yamamoto K; Fukushima Y; Lliev H; Yasui A
Expert Opin Drug Saf; 2022 Oct; 21(10):1315-1328. PubMed ID: 35315729
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of empagliflozin in clinical practice as monotherapy or with other glucose-lowering drugs in Japanese patients with type 2 diabetes: subgroup analysis of a 3-year post-marketing surveillance study.
Kaku K; Nakayama Y; Yabuuchi J; Naito Y; Kanasaki K
Expert Opin Drug Saf; 2023; 22(9):819-832. PubMed ID: 37194266
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study.
Inagaki N; Nishimoto T; Nishiya Y; Nitta D
Expert Opin Drug Saf; 2023 Feb; 22(2):153-163. PubMed ID: 35946927
[TBL] [Abstract][Full Text] [Related]
4. Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study.
Kaku K; Yamamoto K; Fukushima Y; Mizuno S; Nitta D
Expert Opin Drug Saf; 2022 Nov; 21(11):1411-1422. PubMed ID: 35379060
[TBL] [Abstract][Full Text] [Related]
5. Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study.
Kaku K; Chin R; Naito Y; Iliev H; Ikeda R; Ochiai K; Yasui A
Expert Opin Drug Saf; 2020 Feb; 19(2):211-221. PubMed ID: 31769309
[No Abstract] [Full Text] [Related]
6. The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.
Terauchi Y; Usami M; Inoue T
Adv Ther; 2022 Jun; 39(6):2873-2888. PubMed ID: 35449321
[TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT).
Utsunomiya K; Koshida R; Kakiuchi S; Senda M; Fujii S; Kurihara Y; Gunji R; Kaku K
J Diabetes Investig; 2021 Feb; 12(2):184-199. PubMed ID: 32597517
[TBL] [Abstract][Full Text] [Related]
8. Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance.
Inagaki N; Nangaku M; Sakata Y; Sasaki K; Mori-Anai K; Iwasaki T; Hamada K
Adv Ther; 2022 Jan; 39(1):674-691. PubMed ID: 34853985
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT).
Utsunomiya K; Kakiuchi S; Senda M; Fujii S; Kurihara Y; Gunji R; Koshida R; Kameda H; Tamura M; Kaku K
J Diabetes Investig; 2020 Jul; 11(4):906-916. PubMed ID: 32034997
[TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post-marketing study (J-STEP/EL Study).
Kaku K; Naito Y; Senda M; Kurihara Y; Gunji R; Kakiuchi S; Utsunomiya K
J Diabetes Investig; 2020 Mar; 11(2):405-416. PubMed ID: 31390166
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan.
Goda M; Yamakura T; Sasaki K; Tajima T; Ueno M
Curr Med Res Opin; 2018 Feb; 34(2):319-327. PubMed ID: 29025285
[TBL] [Abstract][Full Text] [Related]
12. Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
Kinduryte Schorling O; Clark D; Zwiener I; Kaspers S; Lee J; Iliev H
Adv Ther; 2020 Aug; 37(8):3463-3484. PubMed ID: 32372290
[TBL] [Abstract][Full Text] [Related]
13. Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance.
Moon JS; Kim NH; Na JO; Cho JH; Jeong IK; Lee SH; Mok JO; Kim NH; Chung DJ; Cho J; Lee DW; Lee SW; Won KC
Diabetes Metab J; 2023 Jan; 47(1):82-91. PubMed ID: 35722684
[TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world practice: Results of 12-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
Utsunomiya K; Senda M; Kakiuchi S; Kameda H; Tamura M; Kurihara Y; Gunji R; Fujii S; Kaku K
J Diabetes Investig; 2020 Jan; 11(1):132-141. PubMed ID: 31197929
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan.
Kadowaki T; Haneda M; Ito H; Sasaki K; Yamada Y
Adv Ther; 2020 May; 37(5):2477-2492. PubMed ID: 32323194
[TBL] [Abstract][Full Text] [Related]
16. Japanese study of tofogliflozin with type 2 diabetes mellitus patients in an observational study of the elderly (J-STEP/EL): A 12-week interim analysis.
Utsunomiya K; Shimmoto N; Senda M; Kurihara Y; Gunji R; Kameda H; Tamura M; Mihara H; Kaku K
J Diabetes Investig; 2016 Sep; 7(5):755-63. PubMed ID: 27181254
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
Utsunomiya K; Senda M; Kakiuchi S; Kameda H; Tamura M; Kurihara Y; Gunji R; Fujii S; Fujiwara H; Kaku K
J Diabetes Investig; 2019 Sep; 10(5):1272-1283. PubMed ID: 30702214
[TBL] [Abstract][Full Text] [Related]
18. Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.
Kadowaki T; Inagaki N; Watada H; Sasaki K; Mori-Anai K; Iwasaki T; Teranishi T
Adv Ther; 2022 Apr; 39(4):1642-1658. PubMed ID: 35138572
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials.
Yabe D; Yasui A; Ji L; Lee MK; Ma RCW; Chang TJ; Okamura T; Zeller C; Kaspers S; Lee J; Kohler S; Seino Y
J Diabetes Investig; 2019 Mar; 10(2):418-428. PubMed ID: 30099847
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance.
Ito T; Naito Y; Shimmoto N; Ochiai K; Hayashi N; Okamura T
Expert Opin Drug Saf; 2021 Mar; 20(3):363-372. PubMed ID: 33269625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]